AC Immune Statistics
Total Valuation
AC Immune has a market cap or net worth of $245.38 million. The enterprise value is $91.70 million.
Important Dates
The next estimated earnings date is Tuesday, November 4, 2025, before market open.
| Earnings Date | Nov 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AC Immune has 98.94 million shares outstanding. The number of shares has increased by 8.23% in one year.
| Current Share Class | 98.94M |
| Shares Outstanding | 98.94M |
| Shares Change (YoY) | +8.23% |
| Shares Change (QoQ) | +0.22% |
| Owned by Insiders (%) | 3.60% |
| Owned by Institutions (%) | 4.89% |
| Float | 39.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.84 |
| Forward PS | 129.31 |
| PB Ratio | 2.66 |
| P/TBV Ratio | 8.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.52 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.33, with a Debt / Equity ratio of 0.07.
| Current Ratio | 1.33 |
| Quick Ratio | 1.31 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -301.85 |
Financial Efficiency
Return on equity (ROE) is -50.98% and return on invested capital (ROIC) is -30.36%.
| Return on Equity (ROE) | -50.98% |
| Return on Assets (ROA) | -14.64% |
| Return on Invested Capital (ROIC) | -30.36% |
| Return on Capital Employed (ROCE) | -54.91% |
| Revenue Per Employee | $211,407 |
| Profits Per Employee | -$369,272 |
| Employee Count | 172 |
| Asset Turnover | 0.14 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AC Immune has paid $3,772 in taxes.
| Income Tax | 3,772 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -22.01% in the last 52 weeks. The beta is 1.60, so AC Immune's price volatility has been higher than the market average.
| Beta (5Y) | 1.60 |
| 52-Week Price Change | -22.01% |
| 50-Day Moving Average | 2.18 |
| 200-Day Moving Average | 2.25 |
| Relative Strength Index (RSI) | 64.11 |
| Average Volume (20 Days) | 134,300 |
Short Selling Information
| Short Interest | 1.48M |
| Short Previous Month | 1.49M |
| Short % of Shares Out | 3.10% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 12.69 |
Income Statement
In the last 12 months, AC Immune had revenue of $36.36 million and -$63.51 million in losses. Loss per share was -$0.63.
| Revenue | 36.36M |
| Gross Profit | -42.87M |
| Operating Income | -63.01M |
| Pretax Income | -69.76M |
| Net Income | -63.51M |
| EBITDA | -61.19M |
| EBIT | -63.01M |
| Loss Per Share | -$0.63 |
Full Income StatementBalance Sheet
The company has $159.86 million in cash and $6.19 million in debt, giving a net cash position of $153.68 million or $1.55 per share.
| Cash & Cash Equivalents | 159.86M |
| Total Debt | 6.19M |
| Net Cash | 153.68M |
| Net Cash Per Share | $1.55 |
| Equity (Book Value) | 93.98M |
| Book Value Per Share | 0.93 |
| Working Capital | 41.29M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$53.59 million and capital expenditures -$1.25 million, giving a free cash flow of -$54.89 million.
| Operating Cash Flow | -53.59M |
| Capital Expenditures | -1.25M |
| Free Cash Flow | -54.89M |
| FCF Per Share | -$0.55 |
Full Cash Flow StatementMargins
Gross margin is -117.89%, with operating and profit margins of -173.28% and -174.67%.
| Gross Margin | -117.89% |
| Operating Margin | -173.28% |
| Pretax Margin | -174.66% |
| Profit Margin | -174.67% |
| EBITDA Margin | -168.29% |
| EBIT Margin | -173.28% |
| FCF Margin | n/a |
Dividends & Yields
AC Immune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.23% |
| Shareholder Yield | -8.23% |
| Earnings Yield | -25.88% |
| FCF Yield | -22.37% |
Analyst Forecast
The average price target for AC Immune is $10.00, which is 303.23% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.00 |
| Price Target Difference | 303.23% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 55.95% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AC Immune has an Altman Z-Score of -2.29 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.29 |
| Piotroski F-Score | 3 |
